AllianceBernstein’s Acceleron Pharma XLRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-145,454
| Closed | -$25M | – | 3392 |
|
|
2021
Q3 | $25M | Buy |
145,454
+117,313
| +417% | +$15.3M | 0.01% | 856 |
|
|
2021
Q2 | $3.53M | Buy |
28,141
+1,077
| +4% | +$136K | ﹤0.01% | 1839 |
|
|
2021
Q1 | $3.67M | Buy |
27,064
+216
| +0.8% | +$27.9K | ﹤0.01% | 1740 |
|
|
2020
Q4 | $3.44M | Sell |
26,848
-136
| -0.5% | -$15.9K | ﹤0.01% | 1701 |
|
|
2020
Q3 | $3.04M | Buy |
26,984
+5,280
| +24% | +$526K | ﹤0.01% | 1618 |
|
|
2020
Q2 | $2.07M | Sell |
21,704
-39,596
| -65% | -$3.82M | ﹤0.01% | 1825 |
|
|
2020
Q1 | $5.51M | Sell |
61,300
-5,600
| -8% | -$435K | ﹤0.01% | 1135 |
|
|
2019
Q4 | $3.55M | Sell |
66,900
-50,000
| -43% | -$2.28M | ﹤0.01% | 1625 |
|
|
2019
Q3 | $4.62M | Buy |
116,900
+25,000
| +27% | +$1.08M | ﹤0.01% | 1431 |
|
|
2019
Q2 | $3.77M | Buy |
91,900
+34,500
| +60% | +$1.43M | ﹤0.01% | 1596 |
|
|
2019
Q1 | $2.67M | Sell |
57,400
-155
| -0.3% | -$6.8K | ﹤0.01% | 1746 |
|
|
2018
Q4 | $2.51M | Sell |
57,555
-4,345
| -7% | -$217K | ﹤0.01% | 1705 |
|
|
2018
Q3 | $3.54M | Buy |
61,900
+3,900
| +7% | +$192K | ﹤0.01% | 1533 |
|
|
2018
Q2 | $2.81M | Sell |
58,000
-31,400
| -35% | -$1.14M | ﹤0.01% | 1681 |
|
|
2018
Q1 | $3.5M | Buy |
89,400
+20,400
| +30% | +$867K | ﹤0.01% | 1435 |
|
|
2017
Q4 | $2.93M | Buy |
69,000
+25,850
| +60% | +$970K | ﹤0.01% | 1584 |
|
|
2017
Q3 | $1.61M | Hold |
43,150
| – | – | ﹤0.01% | 1999 |
|
|
2017
Q2 | $1.31M | Hold |
43,150
| – | – | ﹤0.01% | 2154 |
|
|
2017
Q1 | $1.14M | Hold |
43,150
| – | – | ﹤0.01% | 2175 |
|
|
2016
Q4 | $1.1M | Hold |
43,150
| – | – | ﹤0.01% | 2227 |
|
|
2016
Q3 | $1.56M | Hold |
43,150
| – | – | ﹤0.01% | 1955 |
|
|
2016
Q2 | $1.47M | Buy |
43,150
+17,400
| +68% | +$566K | ﹤0.01% | 1964 |
|
|
2016
Q1 | $680K | Buy |
25,750
+1,500
| +6% | +$43.6K | ﹤0.01% | 2296 |
|
|
2015
Q4 | $1.18M | Sell |
24,250
-3,270
| -12% | -$118K | ﹤0.01% | 2029 |
|
|
2015
Q3 | $685K | Sell |
27,520
-78,720
| -74% | -$2.37M | ﹤0.01% | 2357 |
|
|
2015
Q2 | $3.36M | Buy |
106,240
+45,350
| +74% | +$1.46M | ﹤0.01% | 1358 |
|
|
2015
Q1 | $2.32M | Hold |
60,890
| – | – | ﹤0.01% | 1616 |
|
|
2014
Q4 | $2.37M | Buy |
60,890
+6,093
| +11% | +$212K | ﹤0.01% | 1623 |
|
|
2014
Q3 | $1.66M | Buy |
54,797
+29,297
| +115% | +$825K | ﹤0.01% | 1863 |
|
|
2014
Q2 | $866K | Buy |
25,500
+23,900
| +1,494% | +$799K | ﹤0.01% | 2334 |
|
|
2014
Q1 | $55K | Sell |
1,600
-1,600
| -50% | -$72.2K | ﹤0.01% | 3098 |
|
|
2013
Q4 | $127K | Buy |
+3,200
| New | +$77.2K | ﹤0.01% | 2886 |
|
AllianceBernstein's XLRN Position: Q4 2021 in Review
AllianceBernstein sold out of Acceleron Pharma (XLRN) in Q4 2021, closing a stake of 145,454 shares — an estimated $25M sold.
AllianceBernstein first reported a position in XLRN in Q4 2013 and held it in 32 quarters. The position peaked at $25M in Q3 2021. 1 fund tracked by Wall St. Rank holds XLRN as of Q4 2021.
- AllianceBernstein reported no remaining Acceleron Pharma position as of Q4 2021 after selling out during the quarter.
- AllianceBernstein sold 145,454 Acceleron Pharma shares in Q4 2021, an estimated $25M.
- AllianceBernstein first reported a position in Acceleron Pharma in Q4 2013 and held it in 32 quarters.
- AllianceBernstein's Acceleron Pharma position peaked at $25M in Q3 2021.
- 1 fund tracked by Wall St. Rank held Acceleron Pharma as of Q4 2021.
Based on AllianceBernstein's 13F filing for Q4 2021, filed 14 Feb 2022.